systematic_review
    2023
    High Quality

    Oral anticholinergic drugs versus placebo or no treatment for managing overactive bladder syndrome in adults

    Rada Rios D., Deeks J.J., Omar M.I., et al.

    Published in Cochrane Database of Systematic Reviews

    Abstract

    Around 16% of adults have symptoms of overactive bladder. This Cochrane review assessed the effects of anticholinergic drugs compared with placebo or no treatment for managing OAB symptoms in adults.

    Methodology

    Searched Cochrane Incontinence Specialised Register, CENTRAL, MEDLINE for randomized trials comparing anticholinergic drugs to placebo in adults with OAB; used GRADE.

    Key Findings

    Anticholinergic drugs modestly improve OAB symptoms (fewer voids and urgency episodes per 24 hours) compared with placebo, but are associated with higher rates of dry mouth and other anticholinergic side effects.

    Conclusions

    Anticholinergics are effective for reducing OAB symptoms compared with placebo, but the benefit is modest and must be weighed against bothersome adverse effects.

    Limitations

    High heterogeneity, variable outcome reporting, short trial durations, industry funding of many included trials, sparse long-term safety data.

    Related Health Concerns

    Study Details

    Year:2023
    Sample Size:30,000
    Duration:12 weeks
    Quality Score:9/10

    Disclosures

    Funding

    Cochrane infrastructure funding; NIHR (UK)

    Conflicts of Interest

    Review authors declared no financial conflicts; underlying primary trials frequently industry-funded

    This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.